 | http://www.biospace.com/news_story.cfm?StoryID=18681520&full=1
IMI International Medical Innovations (IMI) Release: New Skin Sterol
Data Published In Journal Of Clinical Chemistry
TORONTO, Jan. 12 /PRNewswire-FirstCall/ -- Predictive medicine company
IMI International Medical Innovations Inc. (TSX:IMI; Amex: IME)
announced today that new skin sterol data from a study conducted
independently at the University of Vienna has been published in the
January edition of the Journal of Clinical Chemistry.
"This preliminary study presents some interesting data about the impact
of certain cholesterol-lowering medications on skin sterol values,"
said Dr. Brent Norton, President and Chief Executive Officer. "The
initial data shows that skin sterol may be a useful monitoring tool for
patients taking statins."
A total of 129 patients were tested with PREVU(x) Point of Care Skin
Sterol Test at baseline, and again at follow-up visits six weeks and
six months after the start of the study. Patients also underwent blood
cholesterol testing. Patients were categorized in three groups:
patients taking 40 mg of simvastatin; patients taking 20 mg of
atorvastatin; and a control group of patients who did not receive
lipid-lowering treatment.
Over the course of the study, patients treated with statins experienced
decreases in skin sterol values as well as in blood cholesterol. The
skin sterol levels of patients in the control group increased nominally
from baseline to the six-week follow-up visit and subsequently
declined.
"The relationship between PREVU(x) and various therapies is worthy of
further examination," continued Dr. Norton. "We are currently involved
in additional studies at the University of California at San Francisco,
the Johns Hopkins Bayview Medical Centre and the recently announced
study at the University of British Columbia."
About PREVU(x)
PREVU(x) Point of Care Skin Sterol Test, which does not require fasting
or the drawing of blood, tests the amount of sterol, or cholesterol, in
the skin tissue. Clinical studies have shown that as cholesterol
accumulates on artery walls it also accumulates in other tissues,
including the skin. High levels of skin sterol are correlated with
higher incidence of coronary artery disease (CAD). PREVU(x) POC has
been approved for sale in Canada, the U.S. and Europe.
About IMI
IMI is a world leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. IMI's cardiovascular products, which are branded as PREVU(x)
Skin Sterol Test, will be marketed and distributed worldwide by McNeil
Consumer Healthcare. The company's cancer tests include
ColorectAlert(TM), LungAlert(TM) and a breast cancer test. IMI's head
office is located in Toronto, and its research and product development
facility is at McMaster University in Hamilton, Ontario. For further
information, please visit http://www.imimedical.com/.
This press release contains forward-looking statements. These
statements involve known and unknown risks and uncertainties, which
could cause the Company's actual results to differ materially from
those in the forward- looking statements. Such risks and uncertainties
include, among others, the lack of operating profit and availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the successful development or marketing
of the Company's products, reliance on third-party manufacturers, the
competitiveness of the Company's products if successfully
commercialized, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory
process, and general changes in economic conditions. In addition, while
the Company routinely obtains patents for its products and technology,
the protection offered by the Company's patents and patent applications
may be challenged, invalidated or circumvented by our competitors and
there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. IMI is providing this information as of the
date of this press release and does not undertake any obligation to
update any forward-looking statements contained in this press release
as a result of new information, future events or otherwise.
IMI International Medical Innovations Inc.
CONTACT: Sarah Borg-Olivier, Director, Communications,T: (416)
222-3449, sbolivier@imimedical.com; U.S. Investor: Andrea Faville,The
Investor Relations Group, T: (212)
825-3210,afaville@investorrelationsgroup.com
Related Companies
IMI International Medical Innovations:
Profile , News , Full Quote , Product Pipeline
Related News
News Categories: Research,Diagnostics
Disease Categories: Coronary artery angioplasty,Coronary artery disease
Related Clinical Development Pipelines
Clinical Development: Coronary artery angioplasty,Coronary artery
disease
--------------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore
DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking
|
|
